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Abstract
The pathophysiological mechanisms of both familial and sporadic Amyotrophic Lateral Sclerosis (ALS) are unknown,
although growing evidence suggests that skeletal muscle tissue is a primary target of ALS toxicity. Skeletal muscle biopsies
were performed on transgenic SOD1G93A mice, a mouse model of ALS, to determine genetic biomarkers of disease
longevity. Mice were anesthetized with isoflurane, and three biopsy samples were obtained per animal at the three main
stages of the disease. Transcriptional expression levels of seventeen genes, Ankrd1, Calm1, Col19a1, Fbxo32, Gsr, Impa1,
Mef2c, Mt2, Myf5, Myod1, Myog, Nnt, Nogo A, Pax7, Rrad, Sln and Snx10, were tested in each muscle biopsy sample. Total RNA
was extracted using TRIzol Reagent according to the manufacturer’s protocol, and variations in gene expression were
assayed by real-time PCR for all of the samples. The Pearson correlation coefficient was used to determine the linear
correlation between transcriptional expression levels throughout disease progression and longevity. Consistent with the
results obtained from total skeletal muscle of transgenic SOD1G93A mice and 74-day-old denervated mice, five genes (Mef2c,
Gsr, Col19a1, Calm1 and Snx10) could be considered potential genetic biomarkers of longevity in transgenic SOD1G93A mice.
These results are important because they may lead to the exploration of previously unexamined tissues in the search for
new disease biomarkers and even to the application of these findings in human studies.
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Introduction
According to Biomarkers Definitions Working Group, a
biomarker, which must be objectively measured and evaluated,
is ‘‘an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion’’ as well as ‘‘an indicator of functional and structural changes
in organs and cells’’. Therefore, biomarkers can also be considered
potential therapeutic molecular targets [1].
Amyotrophic Lateral Sclerosis (ALS) is one of the most common
neurodegenerative disorders, and the search for molecular
markers is increasing. This is especially true of the search for
prognostic markers that might be involved in or promote the
neurodegeneration process. These markers can then use to predict
the outcome for a patient who is suffering from the disease.
Because familial and sporadic ALS share clinical and pathological
signs, understanding of the pathophysiological processes in familial
ALS (FALS) would also provide a better understanding of the
neurodegenerative mechanisms in sporadic ALS (SALS) [2]. FALS
follows a predominantly autosomal dominant pattern; in SALS,
genetic factors that occur sporadically contribute to its pathogen-
esis. In particular, mutations in the copper/zinc superoxide-
dismutase-1 gene (SOD1) [3–5], Tar DNA-binding protein gene
(TARDBP) and, most recently discovered, the DNA/RNA-binding
proteins FUS (fused in sarcoma) or TLS (translocation in
liposarcoma) produce the typical adult-onset ALS phenotype,
suggesting that alterations in RNA processing may play a central
role in ALS pathogenesis [6–13].
Interestingly, a wide range of molecules involved in different
molecular pathways in ALS, such as excitotoxicity, inflammation
and oxidative stress, have been described during the last three
decades as possible biomarkers of the disease [14–23]. Many
studies have been carried out to detect molecular markers for the
diagnosis of ALS in tissues such as the brain, spinal cord, blood or
cerebrospinal fluid (CSF).
Although skeletal muscle plays an important role in the
neurophysiological diagnosis of ALS [24,25], growing evidence
supports the fact that it can be considered a primary target of ALS
toxicity [22,26,27]. Under neurodegenerative conditions in ALS,
muscle atrophy can result from lost connections to motor neurons
in the neuromuscular junction; this loss of connections is likely due
to an energetic deficit in the mutant muscle that leads to
pathological conditions [27]. Consequently, skeletal muscle shares
a direct connection with the nervous system and can clearly
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contribute to an alteration in the functional communication
between muscle and nerve. Furthermore, the study of ALS
markers in this tissue suggests that it may be possible to take
muscle biopsy samples from live patients or animal models;
however, this is not the case for brain and spinal cord samples.
The availability of muscle biopsy samples might make it possible to
carry out more accurate studies during disease progression,
especially when markers of the disease have yet to be found.
The transgenic mice that have a G93A mutation in the SOD1
gene (SOD1G93A) are one of the best characterized animal models
for ALS disease and present both clinical and pathological
characteristics of ALS patients [14]. The aim of this study was
to use this mouse model to search for potential genetic biomarkers
of the disease that could be used to predict the animals’ longevity
based on their transcriptional expression during disease progres-
sion. Among the seventeen genes tested, only five, Mef2c, Gsr,
Col19a1, Calm1 and Snx10, may be considered potential genetic
biomarkers of longevity in ALS disease as there was a significant
linear correlation between their transcriptional profile during
disease progression and the longevity of the animals.
Results
Significant variation in gene expression profiles in
transgenic SOD1G93A mice throughout disease
progression
The profile expression pattern of the seventeen genes tested
varied significantly throughout disease progression in the skeletal
muscle of transgenic SOD1G93A mice when compared to control,
age-matched and wild type mice; the exception was Calm1, though
this gene had an irregular expression pattern throughout the three
disease stages. The transcriptional expression levels of Sln, another
gene involved in calcium homeostasis, exhibited a significant
variation in expression, indicating dysfunctions in calcium influx
and calcium-induced endocytosis [28] (Figure 1). Moreover,
Ankrd1 and Col19a1 produced the most significant difference in
transcriptional expression patterns, especially at the terminal stage
of the disease. This indicates there was an increase in muscle
differentiation throughout disease progression that was prompted
by an upregulation of Col19a1 [29] and followed by an
upregulation of Myog, Myod1, Myf5 and Mef2c. Interestingly, the
only myogenic regulatory factor that displayed a downregulation
was Pax7, which would suggest that the myogenic potential and
therefore the capacity for tissue repair were significantly
diminished as neurodegeneration progressed; this finding is in
accordance with the results of previous studies [30]. Significantly,
this neurodegenerative progression also induced an upregulation
in the transcriptional expression levels of Ankrd1 and, to a lesser
extent, Nogo A, Fbxo32 and Snx10, which have previously found to
be altered under degenerative conditions [27,31–35]. Further-
more, we observed a significant upregulation in genes related to
metabolic processes, Impa1, Nnt, Rrad, Gsr and Mt2, which may be
altered under neurodegenerative conditions due to the uncoupled
metabolic pathways they are involved in [36–39].
Transcriptional expression of thirteen genes studied in
muscle biopsies correlated in a linear fashion with
longevity
The correlation study between gene expression profile and
longevity focused on previously studied genes in transgenic
SOD1G93A and age-matched wild type mice. We hypothesized
that those genes whose transcriptional expression yielded statistical
significance during the progression of the disease in transgenic
SOD1G93A mice would be more likely to vary linearly through the
disease stages and that they would correlate with longevity because
they were involved in the neurodegenerative process of ALS.
Figure 1. Transcriptional expression levels of the sixteen genes varied significantly throughout disease progression in transgenic
SOD1G93A mice. Representative graphs showing the fold change in transcriptional levels of the seventeen genes tested in the skeletal muscle of
transgenic SOD1G93A mice throughout disease progression with respect to the early symptomatic stage. Age-matched wild type mice were used as
controls in each stage of the disease: early symptomatic (60 days, grey bar), symptomatic (90 days, blue bar) and terminal (120 days, pale blue bar)
stages. The highest transcriptional expression levels were found in Ankrd1 and Col19a1, which at the terminal stage were almost 27 and 18 times
higher than those observed at the early symptomatic stage, respectively. A significant upregulation of transcriptional levels was found in all of the
genes, except for Calm1, despite its irregular profile pattern throughout disease progression.
doi:10.1371/journal.pone.0032632.g001
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Therefore, the expression patterns of these genes could be used to
predict longevity in transgenic SOD1G93A mice.
The Pearson’s correlation coefficients from each correlation
study are shown in Table 1. The longevity of the mice ranged
between 120 and 160 days. Importantly, we found that the
transcriptional expression levels during disease progression of
thirteen genes, Myf5, Mef2c, Gsr, Myod1, Col19a1, Calm1, Myog,
Snx10, Pax7, Impa1, Mt2, Ankrd1 and Sln, correlated significantly
and negatively with longevity (Table 1). This negative correlation
with longevity implies that the animals that survived longer
displayed lower transcriptional levels of these genes during disease
progression at the early symptomatic stage. Interestingly, unlike
the other genes studied, Mt2 and Nnt, displayed a positive
correlation, which implied a longer survival when the transcrip-
tional levels of Mt2 and Nnt increased during the progression of the
disease at the early symptomatic stage. The highest Pearson’s
correlation coefficients were found when testing Myf5, Mef2c, Gsr,
Myod1 and Col19a1, while the lowest coefficients were found for
Calm1, Myog, Snx10, Pax7, Impa1, Mt2, Ankrd1 and Sln, though they
were still statistically significant. However, the transcriptional
expression levels of Nnt, Fbxo32, Rrad and Nogo A did not display a
significant correlation with longevity. These results suggest that an
increase in myogenic potential may compensate for the muscle
damage induced by the neurodegenerative progression of the
disease, and therefore, the animals that survived longer may
exhibit a higher regenerative capacity than the animals that
survived for less time. It is possible that the animals with a shorter
survival time had exhausted their myogenic regenerative capacity
by overexpressing the myogenic precursors Myf5, Mef2c, Myod1
and Col19a1 at the early stages. This hypothesis is supported by the
results shown in Figure 1 that indicated a significantly diminished
myogenic potential at the terminal stage of 120 days, which is the
shortest survival time among animals included in the muscle
biopsy study.
Furthermore, expression levels of SOD1G93A were measured as
their significant variation could affect disease onset and progres-
sion. No statistical differences were found among the relative
expression levels of SOD1G93A in all the samples obtained from
the three biopsies (Figure 2). This result confirmed the constant
expression levels of SOD1G93A in all the studied biopsies,
suggesting that the neurodegenerative progress of the disease
induced the different gene expression profiles in the studied genes.
From these results, we hypothesized that some of the genes that
presented a significant correlation with longevity were involved in
the denervation process that is present not only in ALS but also in
all other known neurodegenerative disorders. To test this
hypothesis, we used a denervation mouse model. To avoid false
positive results, we tested all seventeen genes.
The expression profiles of eleven genes varied
significantly in the skeletal muscle of denervated mice
In this study, we identified the genes that were significantly
altered in the skeletal muscle of denervated mice to differentiate
the genes that are directly involved in the denervation process due
to the disease from those that may be involved in the specific
neurodegenerative process of ALS.
Among the seventeen genes studied, eleven displayed signifi-
cantly different transcriptional levels in denervated mice compared
to age-matched wild type mice. Similar to the results obtained
from transgenic SOD1G93A mice during disease progression
(Figure 1), the expression levels of Ankrd1, Rrad, Myog, Mt2, Myod1,
Sln, Myf5, Pax7, Nogo A and Impa1 were significantly increased in
denervated mice; Fbxo32, however, displayed a decreased
expression profile (Figure 3). Though the upregulation of Fbxo32
has been associated with ALS [34], its downregulation appears to
be related to an internal mechanism involved in reducing further
loss of muscle proteins in denervation-induced muscle atrophy
[40], which may explain our results. We also observed a
downregulation of the transcriptional levels of Pax7 in transgenic
SOD1G93A mice during disease progression (Figure 1), though in
denervated mice, an overexpression of this gene was detected. This
would suggest that mutant SOD1 toxicity might limit the capacity
of mutant muscle to regenerate because the Pax7-expressing
muscle progenitor pool in denervated muscles may remain less
limited than in mutant muscles [30].
Five potential genetic biomarkers of longevity in ALS
The results observed under denervation conditions show that
among the thirteen genes that displayed a significant correlation
between transcriptional level expression and longevity during
disease progression, five of them, Mef2c, Gsr, Col19a1, Calm1 and
Snx10 may be considered potential biomarkers of longevity in ALS
disease. The linear regression plots for these genes are shown in
Figure 4. These results support the hypothesis that myogenic
potential is significantly favored in animals that display longer
survival and that an increase in transcriptional expression of these
five genes makes it is possible to predict shorter longevity in
transgenic SOD1G93A mice.
Discussion
Since Amyotrophic Lateral Sclerosis (ALS) was discovered and
described in 1869 as a neurodegenerative disease characterized by
motor neuron death and muscular atrophy, a wide range of
biomarkers have been examined in the search for a therapeutic
target. Although ALS shares altered molecular pathways with
other neurodegenerative diseases, such as Alzheimer’s, Hunting-
ton’s or Parkinson’s disease, there is an obvious need for specific
Table 1. Pearson’s correlation coefficients and statistical
significance in the seventeen genes studied in the skeletal
muscle biopsies of transgenic SOD1G93A mice.
Gene Pearson’s correlation coefficient, r p value
MYF5 20,599 0,000
MEF2C 20,552 0,000
GSR 20,547 0,000
MYOD1 20,527 0,000
COL19A1 20,440 0,000
CALM1 20,372 0,000
MYOG 20,339 0,001
SNX10 20,330 0,002
PAX7 20,292 0,007
IMPA1 20,265 0,014
MT2 0,256 0,018
ANKRD1 20,244 0,001
SLN 20,242 0,024
NNT 0,208 0,056
FBXO32 20,188 0,080
RRAD 20,166 0,129
NOGO A 20,161 0,137
doi:10.1371/journal.pone.0032632.t001
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ALS molecular markers that will allow an easier and earlier
prognosis and/or diagnosis.
Because the skeletal muscle may be considered a primary target
of ALS toxicity [22,26,27], we initially tested the gene expression
profiles of seventeen genes using skeletal muscle from transgenic
SOD1G93A mice at different stages of disease progression.
Interestingly, all the genes displayed significant changes in
transcriptional expression throughout the three main stages of
the disease, except for Calm1, though this was probably due to the
high variability in its expression observed throughout the disease
(Figure 1). An increase in the level of Calm1 expression under
degenerative conditions in mutant muscle, especially during the
terminal stage, could activate expression of Mef2c and thereby
activate a regenerative myogenic pathway. Similarly, increasing
levels of Col19a1, Mef2c, Myf5, Myog and Myod1 were also observed
as a regenerative response to the muscle damage [41,42].
However, the decreasing levels of Pax7, especially at the terminal
stage (Figure 1), would indicate that myogenic regeneration was
diminishing at the same time that muscle damage was increasing
in this animal model [30]. According to our results, the
upregulation of the transcriptional expression levels of Ankrd1,
Nogo A, Fbxo32 and Snx10, suggests that muscle damage increases
Figure 2. Transcriptional SOD1G93A fold change in muscle biopsy samples. The transcriptional expression levels of SOD1G93A were
measured in all the samples obtained from the muscle biopsies corresponding to early symptomatic (first biopsy), symptomatic (second biopsy) and
terminal stages (third biopsy). No statistical differences were found in SOD1G93A levels along disease progression. SOD1G93A fold change in the
symptomatic and terminal stages was calculated respect to the relative expression found in all the muscle samples extracted at the early
symptomatic stage.
doi:10.1371/journal.pone.0032632.g002
Figure 3. Eleven genes were related to the denervation process. Fold change variation in the transcriptional levels of seventeen genes in the
skeletal muscle of 74-day-old denervated mice. Wild type mice aged for 60 days were used as controls. Among the seventeen genes tested, the
transcriptional levels of Ankrd1, Rrad, Myog, Mt2, Myod1, Sln, Myf5, Pax7, Nogo A, Impa1 and Fbox32 varied significantly in denervated mice compared
to control mice. Fbox32 was the only gene that displayed a downregulated transcription level in denervated mice, which is probably due to its role in
compensating for denervation-induced muscle atrophy via an internal mechanism.
doi:10.1371/journal.pone.0032632.g003
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throughout disease progression in transgenic SOD1G93A mice
[27,31–35].
Furthermore, our results support those of a recent study in
another mouse model for the disease, transgenic SOD1G86R mice,
which suggested that the aberrant expression of Rrad in response to
oxidative stress may be pathologically relevant [38]. The
increasing transcriptional levels of Gsr and Mt2 in transgenic
SOD1G93A mice could activate the upregulation of Rrad
expression, together with Impa1 and Nnt (Figure 1), prompting
an alteration of the muscle excitation-contraction coupling
regulated by Rrad [38]. This alteration of the muscle could also
be negatively affected by decreasing Sln expression levels, as Sln
regulates relaxation-contraction cycles [43].
We hypothesized from these results that one or more of these
genes, especially Ankrd1 and Col19a1, which showed the highest
significant upregulation during the terminal stage (Figure 1), might
represent a potential prognostic biomarker of the disease. To
elucidate this, biopsy muscle samples from a balanced number of
male and female transgenic SOD1G93A mice were obtained at
three disease stages: the early symptomatic (75 days), symptomatic
(105 days) and endpoint stages. In this last stage, the longevity of
each animal was different, allowing us carry out a correlation study
between longevity and the transcriptional expression profiles of
each gene during disease progression.
Interestingly, the expression of twelve genes, Myf5, Mef2c, Gsr,
Myod1, Col19a1, Calm1, Myog, Snx10, Pax7, Impa1, Ankrd1 and Sln,
during the early symptomatic stage of the disease correlated
significantly and negatively with longevity; Mt2 was the exception
(Table 1). This negative correlation implies that the higher the
expression level of these genes during the progression of the
Figure 4. Mef2c, Gsr, Col19a1, Calm1 and Snx10 are potential genetic biomarkers of longevity in ALS. Linear correlation graphs of five potential
genetic biomarkers of longevity. The graph shows the linear relation between the fold change in transcriptional levels of these genes throughout
disease progression in skeletal muscle biopsies at the early symptomatic stage and the longevity of the animals at the terminal stage. The
transcriptional levels of these genes can predict longevity in transgenic SOD1G93A mice.
doi:10.1371/journal.pone.0032632.g004
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disease, the shorter the survival of the animal. Importantly, the
Myf5, Mef2c, Gsr, Myod1 and Col19a1 genes displayed the highest
Pearson’s coefficients with longevity, suggesting that animals
displaying a downregulation in expression of these genes at the
early symptomatic stage may exhibit a higher regenerative
capacity to compensate for muscle damage, as they survived
longer than animals that overexpressed these genes. Therefore,
because myogenic potential was significantly diminished at 120
days in transgenic SOD1G93A mice (Figure 1), the ability to
maintain this potential and compensate for muscle damage must
closely relate to survival of the animal.
Additionally, Mt2 and Nnt expression levels were positively
correlated with longevity, significantly for Mt2 expression,
suggesting that the upregulation of the t expression levels of these
genes during disease progression could be induced by the
neurodegenerative progress of the disease. However, Mt2 and
Rrad have also been shown, potentially, to be deregulated after
denervation in mouse skeletal muscle [38,44]. Furthermore, it has
been observed that the expression of Nogo A in ALS skeletal muscle
promotes denervation in transgenic SOD1G86R mice [32]. Because
the process of denervation is crucial to inducing muscle atrophy in
ALS, we tested the transcriptional expression of seventeen genes in
the skeletal muscle of denervated mice to determine whether these
genes are related to the denervation process itself; denervation is
present in all known neurodegenerative disorders, including ALS.
Among the seventeen genes studied, the expression profile of
eleven varied significantly in the skeletal muscle of 74-day-old
denervated mice from that in age-matched wild type control mice
(Figure 3). Our results support previously published studies that
found significant variation in the expression levels of Rrad, Mt2 and
Nogo A, together with Ankrd1, Myog, Myod1, Sln, Myf5, Pax7, Impa1
and Fbxo32, in denervated mice. The highest expression profiles
were observed for Ankrd1, Rrad, Myog and Mt2, which were
approximately 20 to 30 times higher than those of controls. This
was especially significant for Ankrd1 expression. These results,
along with those of previous studies [30,32,38,44], suggest that
after 74 days under denervation conditions, skeletal muscle
exhibits damage. This is evidenced by deregulated levels of Ankrd1,
Fbxo32, Nogo A and Rrad causing induction of muscle differentiation
and a subsequent increase in expression levels of Myog, Myod1,
Myf5, Pax7 and Mef2c (although this is not significant for Mef2c) or
overexpression of Mt2, Sln and Impa1 in response to increasing
oxidative stress levels and alterations in calcium and glucose
homeostasis, previously described as characteristics of ALS [22].
In particular, the downregulation of Fbxo32 may suggest that an
internal mechanism is involved in reducing further loss of muscle
proteins during chronic degeneration [40]. Although they were
not significant, the decrease in the expression levels of Calm1, Nnt
and Snx10 may also represent such a mechanism due to their role
in catabolic and anabolic processes that lead to reduced muscle
mass [40]. Similarly, the increase in expression of Col19a1 and Gsr,
though not significant, suggests that there may be concomitant
activation of a second regulatory mechanism that acts as an
effective scavenger of reactive oxygen species [45] or that favors
skeletal myogenesis [29].
Taken together, these results along with the significant Pearson
correlation coefficients observed in muscle biopsies suggest that
Mef2c, Gsr, Col19a1, Calm1 and Snx10 may be considered potential
genetic biomarkers of longevity in a mouse model of ALS
(Figure 4), and the level of their expression in skeletal muscle may
predict the longevity of transgenic SOD1G93A mice.
In summary, the first step of the complex neurodegenerative
process in ALS remains to be elucidated. However, studying the
skeletal muscle as an ALS target tissue that is more accessible than
other tissues, such as the spinal cord or CSF, opens the door to the
discovery of new biomarkers that may lead to more accurate
knowledge of the disease. Our studies suggest that the transcrip-
tional levels of Mef2c, Gsr, Col19a1, Calm1 and Snx10 are closely
related to the neurodegenerative process of ALS in the skeletal
muscle, in such a way that they can predict longevity in a mouse
model for the disease. These observations could help promote
further studies exploring new tissues, and the translation of these
results to human samples may lead to the discovery of new
biomarkers and therefore new potential therapeutic targets.
Materials and Methods
Transgenic SOD1G93A mice
Inbred B6SJL SOD1G93A mice (The Jackson Laboratory, Bar
Harbor, ME, USA) were used in this study because they provide a
suitable ALS disease model. These mice carry a G93A mutation
(substitution of Glycine to Alanine at residue 93) in the human
gene superoxide dismutase 1 (SOD1). Hemizygous mutants,
obtained by crossing a mutant male with a wild-type (WT) female,
were used for all of the experiments. The offspring were identified
by PCR amplification of DNA extracted from tail tissue as
described in The Jackson Laboratory protocol for genotyping
hSOD1 transgenic mice (http://jaxmice.jax.org/pub-cgi/proto-
cols.sh?objtype = protocol,protocolid = 523). The animals were
housed in the Unidad Mixta de Investigacio´n of the University
of Zaragoza, in accordance with international guidelines for the
use of laboratory animals. Food and water were available ad
libitum. Routine microbiological monitoring did not reveal
evidence of infection with common murine pathogens. All of the
experimental procedures were approved by the ethics committees
of our institutions and followed the international guidelines for the
use of laboratory animals, particularly the guidelines for the
preclinical in vivo evaluation of pharmacologically active drugs for
ALS/MND.
Search for gene targets as potential biomarkers of
disease
Based on a previous microarray study of wild type and
transgenic SOD1G93A mice (data not shown) and previously
published results suggesting several possible molecular markers in
the skeletal muscle of an ALS mouse model [46], seventeen genes
were tested as potential biomarkers of ALS disease (Table 2).
Because skeletal muscle was the target tissue, the majority of these
genes are involved in muscle physiology and differentiation. Some
are involved in metabolic and anabolic processes. Neuromuscular
junction dismantlement has been described as the primary
pathogenic event in transgenic SOD1 mice [22]. Among the
genes involved in this neurodegenerative process, cardiac ankyrin
repeat domain 1 (Ankrd1) plays an important role in skeletal muscle
plasticity and appears to be a general marker of muscle damage
when it is upregulated [47], while reticulon 4 (Rtn4, also known as
Nogo A) accelerates the progressive failure of motor neuron
innervation [31,48–50]. Other targets lead more directly to
muscle atrophy when they are upregulated in muscle; these
include F-box only protein (Fbxo32), which enhances proteolysis,
and sorting nexin 10 (Snx10), which promotes vacuolization in
mammalian cells [35,40,51].
The dismantling of the neuromuscular junction is a sign of
muscle denervation, which might be a consequence of skeletal
muscle hypermetabolism. Hypermetabolism leads to a constant
energy deficit in transgenic mice, which precedes amyotrophy and
muscle denervation [52]. Furthermore, glucose metabolism and
calcium homeostasis are altered in this animal model [27]. In
Identification of ALS Biomarkers in a Mouse Model
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particular, possible genes related to glucose metabolism include
inositol (myo)-1(or 4)-monophosphatase 1 (Impa1), which plays an
important role in motor coordination and is directly involved in
glucose metabolism [36]; nicotinamide nucleotide transhydrogen-
ase (Nnt), which leads to appropriate glucose homeostasis in these
mice when it is downregulated [37]; and ras-related associated
with diabetes (Rrad), which promotes altered lipid metabolism and
deregulates glucose uptake [53]. Rrad is also involved in disease
progression, insofar as the accumulation of reactive oxygen species
is coincident with its upregulation [38]. In skeletal muscle,
calmodulin 1 (Calm1) and sarcolipin (Sln) are needed to reach an
adequate calcium influx, which is necessary to either maintain
synaptic transmission in the neuromuscular junction, in the case of
calmodulin1 [54], or to regulate muscle relaxation–contraction
cycles, in the case of sarcolipin [43].
Oxidative stress has also been described in ALS [22]. In
particular, glutathione reductase (Gsr) [39] and metallothionein 2
(Mt2) [55] represent the most studied enzymes involved in this
process. In fact, their deficiency results in muscle atrophy and
oxidative injury.
In contrast to degenerative processes, regenerative processes
tend to compensate for the induced unbalance. In skeletal muscle,
many genes are involved in regenerative pathways, either by
maintaining the integrity of the tissue and favoring skeletal
myogenesis, as is the case for collagen, type XIX, alpha 1 (Col19a1)
[29], or by promoting muscle differentiation and regeneration, as
is the case for the paired box gene (Pax7), myogenic differentiation
1 (Myod1), myogenic factor 5 (Myf5), myocyte enhancer factor 2C
(Mef2c) and myogenin (Myog) [30,56–60].
Extraction of muscle samples in wild type and transgenic
SOD1G93A animals
Hemizygous SOD1G93A mice and age-matched nontransgenic
wild-type control mice at the early symptomatic, symptomatic and
terminal stages (n = 10 transgenic SOD1G93A mice and 10 wild
type mice, balanced males and females, per stage) were used to
study gene expression throughout disease progression. All of the
animals were sacrificed by intraperitoneal (i.p.) injection of sodium
pentobarbital (100 mg/Kg) following the guidelines from the
report of the American Veterinary Medical Association Panel on
Euthanasia, J. Am. Vet. Med. Assoc., 2007 (http://icwdm.org/
Publications/pdf/ControlMethods/Euthanasia/AVMA2007report.
pdf.
All surgical material was sterilized before dissection. After
dissection, skeletal muscle of the hind limbs was immediately
frozen in liquid nitrogen and stored at 280uC. Samples were
collected by simple random sampling using the Statistical Package
for the Social Sciences (SPSS) 15.0.
Extraction of biopsies from skeletal muscle of transgenic
SOD1G93A mice
Forty-eight transgenic SOD1G93A male and female mice were
used to study the correlation of gene expression with longevity
Table 2. Functional role and related molecular pathway of the seventeen genes studied.
GENE NAME SYMBOL GENE ID FUNCTION MOLECULAR PATHWAY
ankyrin repeat domain 1 (cardiac muscle) Ankrd1 107765 marker of muscle damage
muscle plasticity
F-box only protein 32 Fbxo32 67731 promotes skeletal muscle atrophy MUSCLE DAMAGE
reduction of its gene expression levels in spinal cord
injury disorders
sorting nexin 10 Snx10 71982 regulation of endosome homeostasis
paired box gene 7 Pax7 18509 muscle development
myogenic differentiation 1 Myod1 17927 myogenesis, muscle differentiation MUSCLE DIFFERENTIATION
myogenic factor 5 Myf5 17877 regulator of regenerative myogenesis and homeostasis,
muscle regeneration
AND REGENERATION
myocyte enhancer factor 2C Mef2c 17260 maintenance sarcomere integrity, muscle differentiation
myogenin Myog 17928 differentiation of muscle cells
collagen, type XIX, alpha 1 Col19a1 12823 esophageal muscle development and function MAINTENANCE MUSCLE INTEGRITY
reticulon 4 NOGO A 68585 inhibitor axonal regeneration AND MUSCLE REINNERVATION
calmodulin 1 Calm1 12313 calcium signal modulator
endocitosis mediator at nerve terminal CALCIUM HOMEOSTASIS
sarcolipin Sln 66402 regulator calcium transport and muscle relaxation-
contraction cycles
inositol (myo)-1(or 4)-monophosphatase 1 Impa1 55980 inositol homeostasis
activated target of calbindin
nicotinamide nucleotide transhydrogenase Nnt 18115 glucose homeostasis GLUCOSE METABOLISM
ras-related associated with diabetes Rrad 56437 glucose tolerance and insuline sensitivity
regulation intracellular calcium signalling
glutathione reductase Gsr 14782 oxidative stress metabolism
metallothionein 2 Mt2 17750 metal binding and free radical scavenging properties OXIDATIVE STRESS
oxidative stress metabolIsm, zinc homeostasis
doi:10.1371/journal.pone.0032632.t002
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(n = 24 mice per sex). Three muscle biopsies from the Gluteus
superficialis muscle were obtained per mouse, from a different hind
limb each time, at three different ages that coincided with the
early symptomatic stage (75 days), symptomatic stage (105 days)
and terminal stage (endpoint age). This innovative procedure
allowed the study of gene expression in the same animal; it was
possible to keep the animal alive at different disease stages
throughout the study because the Gluteus superficialis muscle is
easily to reach and its manipulation does not prevent the mouse
from moving properly after each surgery. All surgical material
was sterilized before the extraction. Twenty minutes before
starting the extraction, the analgesic Meloxicam 2 mg/kg
(Metacam AINES Cox-2) was administered subcutaneously to
the animal. Once the gluteus superficialis muscle was localized,
the zone was shaved and then disinfected with 70% alcohol and
povidone iodide.
Each mouse was anesthetized by administration of isoflurane
(4–5%) and a constant flux of 1.5–2% isoflurane maintained using
a facemask. The lack of motor reflexes was confirmed before
starting the surgery. The body temperature was maintained at a
constant level with a thermal blanket, and a moisturizer gel
(Lubrithal) was applied on the eyes to prevent corneal damage
during the extraction.
Once the animal was prepared for surgery, an incision of
,1 cm was made on the zone where the gluteus superficialis is
localized. The connective tissue around this muscle was carefully
removed. A small biopsy of the muscle, with a weight of
approximately 3 mg (<1 mm2), was transferred to an eppendorf
tube containing RNAlaterH solution (AM7021, Ambion, Madrid,
Spain) to preserve the extracted tissue. The zone was closed with
staples (EZ 9 mm clip) and rehydrated with physiological serum
0.9%, and a scar gel (Aloe vet) was applied to promote
cicatrisation of the wound. The mouse was placed back into its
cage,, and it’s body temperature was maintained using an infrared
lamp until it awoke. The cage contained hydrated food and paper
to facilitate the recovery of the animal.
For 24 hours following surgery, the mouse was tested two times
per day to check coordination and to ensure the viability of the
next biopsy. One week following surgery, the staples were
removed. This methodology was repeated in each animal for the
three selected stages so that the three biopsy samples were
obtained from each mouse were of from the same kind of muscle
[61]. The final biopsy sample was extracted at the endpoint for
each animal. The mice were sacrificed when they were unable to
right themselves within 30 s after being placed on their side; this
point was considered the survival endpoint according to the
guidelines for preclinical testing and colony management [62,63].
Extraction of muscle samples in denervated animals
Six male wild-type mice of the B6CLJ strain were anesthetized
(pentobarbital 30 mg/kg, i.p.) at the age of 60 days, and muscle
denervation was performed following the methodology described
previously [30]. After surgical denervation, the animals were
sacrificed by cervical dislocation at 74 days of age, and the
gastrocnemius muscles were dissected and frozen immediately in
liquid nitrogen.
RNA extraction, synthesis of cDNA and real time PCR
assay
RNAlaterH solution was removed from the biopsy samples, and
total RNA was extracted using the RNeasy Micro Kit protocol
(74004, Qiagen-Izasa, Barcelona, Spain), which included treat-
ment with Dnase I solution to eliminate genomic DNA.
Tissue samples from the skeletal muscle of transgenic
SOD1G93A, wild type, denervated, heterozygous and hemizygous
SMA mice were pulverized in liquid nitrogen in a cold mortar. In
this group of samples, total RNA was extracted using TRIzol
Reagent according to the manufacturers’ protocol (Invitrogen
S.A., Prat de Llobregat, Spain). RNA was treated to eliminate
genomic DNA using the Turbo DNA-freeTM kit (AM1907,
Ambion, Madrid, Spain).
RNA extracted from both groups of samples was processed for
reverse transcription (RT) using the SuperScriptTM First-Strand
Synthesis System kit (12371-019, Invitrogen S.A., Prat de
Llobregat, Spain). Gene expression variations in all of the samples
were assayed by real-time PCR. PCR reactions were carried out in
a StepOneTM Real-Time PCR System (4387925, Applied
Biosystems, Madrid, Spain). Primer and probe mixtures for each
gene of interest were supplied by Applied Biosystems (Madrid,
Spain) (Table 3).
Reactions were performed in a final volume of 5 mL with 16
TaqManH Fast Universal PCR Master Mix (4352042, No
AmpEraseH UNG, Applied Biosystems, Madrid, Spain), 16 of
the primer and TaqManH MGB probe mix for each studied gene
and 2 mL of 106 diluted cDNA per reaction. Three endogenous
genes (18S rRNA, GAPDH, and b-actin) were used for
normalization following the methodology described previously
[64]. All reactions were performed in triplicate and all reaction
efficiencies of the primer/probe sets were close to 100%. Thermal
cycling parameters were as follows: incubation at 95uC, 20 sec-
onds, and 40 cycles of 95uC for 1 second and 60uC for 20 seconds.
Gene expression analysis in total skeletal muscle samples
of transgenic SOD1G93A and denervated mice
Changes in the RNA expression levels of each gene were studied
in the skeletal muscles samples of mice, balanced for males and
females. The corresponding DCT values of each extracted sample
were normalized with geometric media of the selected housekeep-
ing genes as described above. Age-matched wild type mice were
used as controls when studying the disease progression in
transgenic SOD1G93A mice. Sixty-day-old wild-type mice were
used as controls when studying the expression patterns of the
selected genes in denervated mice.
The DDCT method was used to determine relative changes in
transcriptional expression. Statistical analyses of the data were per-
formed using the fold change 2{DDCT
 
as previously described [64].
Longevity correlation analysis of muscle biopsy samples
For each gene studied, the DDCT method was used to
determine relative changes in gene expression, as previously
described. Differences in the threshold cycles between the DCT
value at 75 days and at 105 days/the endpoint stage were
calculated in all the tested genes for each animal under study.
Because the first muscle biopsy sample was obtained when the
animals showed early disease symptoms (75 days), DCT 75 days was
taken as a reference parameter to calculate the variation in the
relative gene expression at the symptomatic (105 days) and
endpoint stages with respect to the early symptomatic stage (75
days). Using this methodology, the corresponding fold changes
were calculated using the equation 2{DDCT . In this way, for each
animal, three fold change values were obtained for each gene and
were plotted to calculate the slope. The linear regression between
each slope value for each animal and the age at which the animal
died was studied. The Pearson correlation coefficient was used to
determine the linear correlation between the slopes obtained for
each studied gene and the longevity data.
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Statistical analysis
Statistical analyses were carried out using the non-parametric
Mann-Whitney test to evaluate the variability in gene expression.
The Pearson correlation coefficient was used to determine the
linear correlation in wild type and transgenic SOD1G93A mice
with longevity throughout disease progression. All of the values
were expressed as the mean 6 S.E.M. The statistical significance
threshold was set at p,0.05. The software used for the statistical
analysis was SPSS 15.0.
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